Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The IGF pathway is activated in insulinomas but downregulated in metastatic disease.

Henfling M, Perren A, Schmitt AM, Saddig CM, Starke AA, Riedl RG, Versleijen-Jonkers YMH, Sprij-Mooij DM, Ramaekers FCS, Hofland L, Speel EM.

Endocr Relat Cancer. 2018 Jul 18. pii: ERC-18-0222. doi: 10.1530/ERC-18-0222. [Epub ahead of print]

PMID:
30021864
2.

Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma.

van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA, Fleuren EDG.

Mol Cancer Ther. 2018 Jul;17(7):1365-1380. doi: 10.1158/1535-7163.MCT-17-1131. Review.

PMID:
29967215
3.

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

van Erp AEM, Hillebrandt-Roeffen MHS, van Houdt L, Fleuren EDG, van der Graaf WTA, Versleijen-Jonkers YMH.

Target Oncol. 2017 Dec;12(6):815-826. doi: 10.1007/s11523-017-0528-z.

4.

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.

van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, van Houdt L, Gorris MAJ, van Dam LS, Mentzel T, Weidema ME, Savci-Heijink CD, Desar IME, Merks HHM, van Noesel MM, Shipley J, van der Graaf WTA, Flucke UE, Meyer-Wentrup FAG.

Oncotarget. 2017 Jul 7;8(41):71371-71384. doi: 10.18632/oncotarget.19071. eCollection 2017 Sep 19.

5.

Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes.

Fleuren EDG, Vlenterie M, van der Graaf WTA, Hillebrandt-Roeffen MHS, Blackburn J, Ma X, Chan H, Magias MC, van Erp A, van Houdt L, Cebeci SAS, van de Ven A, Flucke UE, Heyer EE, Thomas DM, Lord CJ, Marini KD, Vaghjiani V, Mercer TR, Cain JE, Wu J, Versleijen-Jonkers YMH, Daly RJ.

Cancer Res. 2017 Aug 15;77(16):4279-4292. doi: 10.1158/0008-5472.CAN-16-2550. Epub 2017 Jun 20.

6.

Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.

Vlenterie M, Hillebrandt-Roeffen MH, Schaars EW, Flucke UE, Fleuren ED, Navis AC, Leenders WP, Versleijen-Jonkers YM, van der Graaf WT.

Ann Surg Oncol. 2016 Sep;23(9):2745-52. doi: 10.1245/s10434-016-5341-x. Epub 2016 Jun 22.

7.

Next generation sequencing in synovial sarcoma reveals novel gene mutations.

Vlenterie M, Hillebrandt-Roeffen MH, Flucke UE, Groenen PJ, Tops BB, Kamping EJ, Pfundt R, de Bruijn DR, Geurts van Kessel AH, van Krieken HJ, van der Graaf WT, Versleijen-Jonkers YM.

Oncotarget. 2015 Oct 27;6(33):34680-90. doi: 10.18632/oncotarget.5786.

8.

High prevalence of late adverse events in malignant bone tumour survivors diagnosed at adult age.

van de Luijtgaarden AC, Kapusta L, Bellersen L, Bokkerink JP, Kaal SE, Versleijen-Jonkers YM, Schreuder HW, van der Graaf WT.

Neth J Med. 2014 Dec;72(10):516-22.

9.

The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.

Fleuren ED, Hillebrandt-Roeffen MH, Flucke UE, Te Loo DM, Boerman OC, van der Graaf WT, Versleijen-Jonkers YM.

Oncotarget. 2014 Dec 30;5(24):12753-68.

10.

Solitary fibrous tumor - clinicopathologic, immunohistochemical and molecular analysis of 28 cases.

Vogels RJ, Vlenterie M, Versleijen-Jonkers YM, Ruijter E, Bekers EM, Verdijk MA, Link MM, Bonenkamp JJ, van der Graaf WT, Slootweg PJ, Suurmeijer AJ, Groenen PJ, Flucke U.

Diagn Pathol. 2014 Nov 29;9:224. doi: 10.1186/s13000-014-0224-6.

11.

Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.

Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, Franssen GM, Flucke UE, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT.

Int J Cancer. 2014 Dec 15;135(12):2770-82. doi: 10.1002/ijc.28933. Epub 2014 May 5.

12.

Theranostic applications of antibodies in oncology.

Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, Boerman OC.

Mol Oncol. 2014 Jun;8(4):799-812. doi: 10.1016/j.molonc.2014.03.010. Epub 2014 Mar 21. Review.

13.

Anti-angiogenic therapy, a new player in the field of sarcoma treatment.

Versleijen-Jonkers YM, Vlenterie M, van de Luijtgaarden AC, van der Graaf WT.

Crit Rev Oncol Hematol. 2014 Aug;91(2):172-85. doi: 10.1016/j.critrevonc.2014.02.001. Epub 2014 Feb 15. Review.

PMID:
24613529
14.

Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.

Fleuren ED, Versleijen-Jonkers YM, Boerman OC, van der Graaf WT.

Biochim Biophys Acta. 2014 Apr;1845(2):266-76. doi: 10.1016/j.bbcan.2014.02.005. Epub 2014 Feb 28.

PMID:
24582852
15.

IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization.

van de Luijtgaarden AC, Roeffen MH, Leus MA, Flucke UE, Schreuder BH, van der Graaf WT, Versleijen-Jonkers YM.

Future Oncol. 2013 Nov;9(11):1733-40. doi: 10.2217/fon.13.118.

PMID:
24156333
16.

Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.

van Gaal JC, Roeffen MH, Flucke UE, van der Laak JA, van der Heijden G, de Bont ES, Suurmeijer AJ, Versleijen-Jonkers YM, van der Graaf WT.

Eur J Cancer. 2013 Nov;49(16):3462-70. doi: 10.1016/j.ejca.2013.06.022. Epub 2013 Jul 15.

PMID:
23867124
17.

αB-crystallin expression is correlated with phospho-ERK1/2 expression in human breast cancer.

van de Schootbrugge C, van Asten F, Nagtegaal ID, Versleijen-Jonkers YM, van Laarhoven HW, Roeffen MH, Sweep FC, Bussink J, Kaanders JH, Pruijn GJ, Boelens WC, Span PN.

Int J Biol Markers. 2013 Dec 17;28(4):e365-70. doi: 10.5301/jbm.5000032.

PMID:
23722303
18.

The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.

Fleuren ED, Versleijen-Jonkers YM, Heskamp S, Roeffen MH, Bouwman WH, Molkenboer-Kuenen JD, van Laarhoven HW, Oyen WJ, Boerman OC, van der Graaf WT.

Eur J Cancer. 2013 Sep;49(13):2851-8. doi: 10.1016/j.ejca.2013.04.009. Epub 2013 May 8.

PMID:
23664098
19.

Hypoxia regulation of phosphokinases and the prognostic value of pAKT in breast cancer.

Wennemers M, Stegeman H, Bussink J, Versleijen-Jonkers YM, van Laarhoven HW, Raleigh JA, Varia MA, Sweep FC, Span PN.

Int J Biol Markers. 2013 Jun 28;28(2):151-60. doi: 10.5301/jbm.5000008.

PMID:
23558942
20.

Expression and clinical relevance of MET and ALK in Ewing sarcomas.

Fleuren ED, Roeffen MH, Leenders WP, Flucke UE, Vlenterie M, Schreuder HW, Boerman OC, van der Graaf WT, Versleijen-Jonkers YM.

Int J Cancer. 2013 Jul 15;133(2):427-36. doi: 10.1002/ijc.28047. Epub 2013 Feb 25.

21.

Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.

van de Luijtgaarden AC, Versleijen-Jonkers YM, Roeffen MH, Schreuder HW, Flucke UE, van der Graaf WT.

Target Oncol. 2013 Dec;8(4):253-60. doi: 10.1007/s11523-012-0248-3. Epub 2013 Jan 6.

PMID:
23292309
22.

Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.

van Gaal JC, Flucke UE, Roeffen MH, de Bont ES, Sleijfer S, Mavinkurve-Groothuis AM, Suurmeijer AJ, van der Graaf WT, Versleijen-Jonkers YM.

J Clin Oncol. 2012 Jan 20;30(3):308-15. doi: 10.1200/JCO.2011.37.8588. Epub 2011 Dec 19.

PMID:
22184391
23.

Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.

Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, Roeffen MH, van Laarhoven HW, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT.

Clin Cancer Res. 2011 Dec 15;17(24):7693-703. doi: 10.1158/1078-0432.CCR-11-1488. Epub 2011 Oct 28.

24.

Targeted therapy for Ewing's sarcoma: significance of heterogeneity.

Van De Luijtgaarden AC, Van Der Graaf WT, Otte-Höller I, Schreuder HW, Versleijen-Jonkers YM, Slootweg PJ.

Anticancer Res. 2010 Sep;30(9):3715-9.

PMID:
20944159
25.

ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model.

Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT, Boerman OC.

J Nucl Med. 2010 Oct;51(10):1565-72. doi: 10.2967/jnumed.110.075648. Epub 2010 Sep 16.

Supplemental Content

Loading ...
Support Center